Index

Aberrant Behavior Checklist (ABC) 18, 312
acetaminophen 87
traumatic brain injury (TBI) 55
adenoma sebaceum 58
adrenoleukodystrophy 312
affect 19
affirmations 290
agenesis of corpus callosum 59
aggression 210–12
assessment, emergency 223–4
history taking 224–6
management strategy 225
organization 224
summary 226
assessment, multimodal model 223
assessment, ongoing 226–7
biopsychosocial model 220
biological component 220–1
psychological component 221–2
social component 222
clinical pearls
patients with ID 244–5
pharmacologic treatment 241
cognitive processes 217–18
comorbidities 216–17
associated psychiatric and medical conditions 217
comprehensive approach 241–4
correlates in persons with ID 214–16
differential diagnosis 228
etiologies 228
interpretations of behavior problems 242
laboratory evaluation 221
life transitions 219–20
mood and anxiety disorders 218

potential functions of problem behavior 224
prevalence rates 212–13
psychotic disorders 218
risk factors 219
syndromes associated with SIB 218–19
treatment strategies 240
electroconvulsive therapy (ECT) 239–40
treatment strategies, hormonal 239
treatment strategies, non-pharmacological 227–9
intervention levels 229
psychotherapy 229–31
treatment strategies, pharmacologic antidepressants 236–7
antipsychotic medications 232–4
benzodiazepines 237
beta blockers 238
mood stabilizers/anticonvulsants 235–6
opioid antagonists 237
overview 231–2
psychostimulants 238–9
aging, premature 27
akathisia 33
alcohol-induced psychotic disorder 184
alcohol-related birth defects (ARBD) 346
alcohol-related neurodevelopmental disorders (ARND) 346
alopecia areata 27
altered consciousness (AOC) 77
Alzheimer’s disease 27
amitriptyline 130
Angelman syndrome 52–3
anger facial expression 104
antecedent control 316
Antecedent, Behavioral, Consequence (ABC) model 291, 309–12
anticonvulsants
aggression 236
ID 264–5
traumatic brain injury (TBI) 87
antidepressants
aggression 236–7
ID 266–9
antipsychotic medications 33, 64
antipsychotics 186
aggression 232–4
distribution 193
antisocial personality disorder (APD) 192, 201–3
anxiety disorders 146, 157–8
aggression 218
generalised anxiety disorder (GAD) 154–5
obsessive compulsive disorder (OCD) 150–2
panic disorder 149–50
post-traumatic stress disorder (PTSD) 152–4
prevalence 146–8
treatments 155
pharmacologic interventions 155–7
psychotherapeutic interventions 157
anxiolytics
ID 266–9
aripiprazole
Fragile X syndrome (FXS) 34–5
Asperger’s syndrome
see also autism spectrum disorders (ASDs)
self-stimulation 169
assessment of patients see medical assessment;
psychiatric assessment
assistive devices 118
asylums 1, 3–4
ataxia 58
ataxia telangiectasia 56, 61
atomoxetine
aggression 239
ataxia of corpus callosum 59
attention deficit hyperactivity disorder (ADHD)
attention span 112
fetal alcohol syndrome (FAS) 348
nonverbal behavior 103
attention span 112
inattention during evaluation 112–13
atypical antipsychotics 186
traumatic brain injury (TBI) 87
auditory hallucinations 171
Autism Speaks 4
autism spectrum disorders (ASDs) 59, 355
behavioral phenotype 357–8
cognitive functioning 357
genetics 356–7
medical issues 355–6
nonverbal behavior 103
psychopathology 358–9
self-stimulation 169
autoimmune disorders 27
automatic thoughts 290
avoidant personality disorder 192
Babinski reflex 62
Bachman–de Lang syndrome see Cornelia de Lange syndrome
baclofen 64
Bardet–Biedl syndrome 61
basal-ganglia-related disorders 59
baseline exaggeration 15, 17, 22–3, 95–7
Batten disease 61
behavior analysis
psychiatric assessment instruments 18
behavior support services
coordination 319–22
keys to success 322–3
plans 318–19
summary form 322
behavioral assessment 309–14
psychiatric problems 314–15
behavioral focus
aggression 230
behavioral intervention 315–16
benzodiazepines 33
aggression 232, 237
anxiety disorders 157
ID 267–8
psychotic disorders 186
bereavement 40
beta blockers
aggression 238
biopsychosocial model
aggression 220
biological component 220–1
psychological component 221–2
social component 222
psychotropic medications in ID 252
bipolar disorder (BD) 126
prevalence and predisposing factors 133–5
treatments 138–41
blink rates 151
blood vomiting 39
body manipulator nonverbal communications 104
body mass index (BMI) 37
borderline learning difficulties 9
borderline personality disorder (BPD) 192, 195–9
treatment 204
breast cancer 44
brief psychotic disorder 180
bupropion 130
bupropion-induced psychosis 185
Index 367
Index

buspirone
  anxiety disorders 156
  ID 268
  tardive conditions 65

café-au-lait spots 54

caffeine
  traumatic brain injury (TBI) 87
  cancer 44–5

carbamazepine 139, 141
  aggression 235
  ID 264
  psychotic disorders 186

carbidopa 22

cardiovascular system 33–7

catatonic behavior 172

cerebellar disorders 59

cervical cancer 44

cell analysis 291

cherry red spots 61

Children’s Depression Inventory (CDI) 18

citalopram 130
  anxiety disorders 156
  clasped-knife finding 62

classification of ID (mental retardation) 5

clozapine
  anxiety disorders 156

clonazepam
  anxiety disorders 156

clonidine
  tardive conditions 65

Closing The Gap 35

clozapine 34, 139
  aggression 233, 234

cognition 20

cognitive approaches
  aggression 230

cognitive behavioral therapy (CBT) 290–3

  mood disorders 129–30

cognitive disintegration 15, 95

  cognitive processes 93
  concrete thinking 93–4

  egocentrism 94

  magical thinking 93

  pre-logical thinking 93

  colon cancer 44

  communication issues 283–5

  feeling states 285–6

  communicative skill categories 92

  competency to stand trial 334–6

  compulsive behavior disorder 156

  concrete operations 164

  concrete speech 100

  concrete thinking 93–4

  confidentiality of patients 283

  congenital hemiplasia 58

  consciousness 290

  consequences 316–18

  constipation 39

Cornelia de Lange syndrome (Bachman–de Lange syndrome) 52, 60

  self-injurious behavior (SIB) 219

  coronary heart disease 37

  corpus callosum

  agenesis 59

  atonia 59

  corticosteroid-induced psychosis 185

  countertransference

  aggression 229–30

  cranial nerve problems 60–2

  cultural awareness and sensitivity 118–19

  beliefs about disability 119

dantrolene

  psychotic disorders 186

de Clerambault’s Syndrome 179

delirium 171

delusional disorder 179

delusions 171–2

dementia 28

  dementia praecox 170

  dependent personality disorder 192

  distribution 193

  Depo-Provera 42, 43

  depression

  psychiatric assessment instruments 18

  desipramine 130

  development of discrepancy 289

  Developmental Behaviour Checklist (DPC-P) 18

  Developmental Behaviour Checklist for Adults (DBC-A) 18

  diabetes mellitus 38

  diagnosis of ID (mental retardation)

    see also medical assessment; psychiatric assessment

    assessment instruments, standardised 18

    criteria

    AAIDD definition 9

    DC-LC criteria for learning difficulties 9

    DSM-5 proposed criteria 10

    international classification 5–8

    differential diagnosis 21

    studies 20–1

  diagnostic manual–intellectual disability (DM-ID) 170

  diagnostic overshadowing 147

  Diagnostic psychiatric assessment Schedule for Severely Handicapped-II (DASH-II) 18

  dialectical behavior therapy (DBT) 204–7, 293–5

  diazepam 39, 64

  differential reinforcement of alternative behavior (DRA) 317
differential reinforcement of incompatible behavior (DRI) 317
aggression 237
anxiety disorders 156
differential reinforcement of low rates (DRL) 317
fluoxetine-induced psychosis 185
differential reinforcement of other behavior (DRO) 317
folie à deux (shared psychotic disorder) 181
DiGeorge syndrome 53–4
folie communiqué 181
dimenhydrinate
foulard 2
traumatic brain injury (TBI) 87
Fragile X syndrome (FXS) 28, 52, 60, 351
disability benefits 331–2
behavioral phenotype 353
disgust facial expression 104
clinical vignette 34–5
divalproex sodium 141
cognitive functioning 352–3
dopaminergic drug-induced psychosis 185
interviewing techniques 105
doubling (psychodrama technique) 299
drug-induced psychosis 185
Down syndrome (DS) 27–8, 338–9
psychopathology 353–5
treatment of other behavior
stereotypies 58
behavioral phenotype 341
treatment of other behavior
expressed emotion (EE) 118
behavioral phenotype 341
treatment of other behavior
expressing empathy 289
behavioral phenotype 341
externalizing behavior symptom 212
treatment of other behavior
evaluating the behavior 212
extrapyramidal side effects (EPS) 33, 35
extrapyramidal risk factors 219
extrapyramidal side effects (EPS) 33, 35
echolalia 172
evaluating the behavior 212
edema 29
evaluating the behavior 212
egozentrism 94
evaluating the behavior 212
electroconvulsive therapy (ECT) agression 239–40
et al. 18
aggression 239–40
electroconvulsive therapy (ECT)
mood disorders 131
aggression 239–40
emblem nonverbal communications 104
agression 239–40
encephalotrigeminal angiomatosis 55–6
agression 239–40
environmental setting conditions 223
agression 239–40
epilepsy 67
agression 239–40
estrogens 257
agression 239–40
expressed emotion (EE) 118
agression 239–40
expressing empathy 289
agression 239–40
externalizing behavior symptom 212
agression 239–40
extrapyramidal side effects (EPS) 33, 35
agression 239–40
facial expressions 103–4
agression 239–40
fear facial expression 104
agression 239–40
feeble-mindedness 6
agression 239–40
fetal alcohol effects (FAE) 346
agression 239–40
fetal alcohol spectrum disorder (FASD) 345–6
behavioral deficits 349–51
cognitive deficits 348
diagnosis 346–7
medical conditions 347–8
fetal alcohol syndrome 57–8
fluoxetine 130
fluoxetine 130

Index

369
histrionic personality disorder (HPD) 200–1
distribution 193
hormonal treatment
aggression 239
Huntington’s disease (HD) 58, 61
hydrocephalus 61
5-hydroxyindoleacetic acid (5-HIAA) 232
hyperacusis 29
hypercholesterolemia 37
hyperlipidemia 34
hyperphagia 29
hyperprolactinemia 257
hypertension 34, 37
white coat 47
hypogonadism 29
hypomania 17, 126
hypothyroidism 27, 29
hypotonia 27, 29
idiocy 3, 8
illustrator nonverbal communications 104
imbecility 7
imipramine 130
impulsive personality disorder
distribution 193
incontinence 28
individual setting conditions 223
informed consent 327–30
assessing capacity 328
substitute decision-maker 328–9
intellectual disability (ID)
behavioral presentations 30–1
comorbid psychiatric and habit disorders
256
current treatment recommendations 4
diagnostic criteria 5–8
historical perspective 251
biopsychosocial model 252
historical perspective
pre-Enlightenment ideas 1–3
reformers 3–4
interface with mental illness 11–12
life expectancy 26–7
nomenclature 8–10
non-pharmacological interventions 252
People First language 10–11
pharmacological interventions 252–3
prevalence and classification 4–5
problem behaviors (PB) 253–6
sexual aggression 256–8
intellectual distortion 15, 17, 94
interviewing techniques 15–16, 90–1, 121–2
acquiescence 110–11
management 111–12
assistive devices 118
attention span 112
inattention during evaluation 112–13
attitude of interviewer 119
baseline exaggeration 95–7
clinical pearls 122
cognitive disintegration 95
cognitive processes 93
cognitive distortion 95
concrete thinking 93–4
ego centricity 94
magical thinking 93
pre-logical thinking 93
cultural awareness and sensitivity 118–19
beliefs about disability 119
expressed emotion (EE) 118
formal mental status examination 97
summary 98–9
guidelines 108–9
intellectual distortion 94
interpreting mental examination findings
mild ID 97–101
moderate ID 101
severe/profound ID 102–4
language skills 91–2
categories of communicative skills 92
level of ID 91
medical problems 116–17
memory 113–14
interactions during treatment 114–15
saliency 114
open-ended questions 115–16
perseveration 110
personality traits 105
psychological masking 95
psychotic disorders 163–5
responsiveness 115
sensory deficits 117
sensory hypersensitivity 117
serial order effects 113
setting the stage 92–3
social skills 115
specific disorders
Down syndrome (DS) 105
Fragile X syndrome (FXS) 105–8
Williams syndrome (WS) 108
subvocalizations 110
suspects 120–1
victims 120–1
witnesses 120–1
intoxication
nonverbal behavior 103
IQ
AAIDD definition of mental retardation 9
DC-LD criteria for learning disabilities 9
international criteria for mental retardation
6–8
journaling 291
Kayser–Fleisher rings 58, 61
Krabbe leukodystrophy 58

laboratory testing 32–3
Landau–Kleffner syndrome (LKS) 67
learning difficulties 9
learning issues 286
legal issues 325–6, 336–7
evaluation of persons with ID 330–1
competency to stand trial 334–6
disability benefits 331–2
petitions for guardianship 332–4
treatment of persons with ID
informed consent 327–30
right to reasonable modifications 326–7
Lennox–Gastaut seizures 67
Lesch–Nyhan syndrome 219
levetiracetam-induced psychosis 185
levodopa 22
life expectancy of individuals with ID 26–7
Lisch nodules 54, 61
lithium 130, 141
aggression 235–6
ID 264
loss of consciousness (LOC) 77
Lowe’s syndrome 61
luteinizing hormone releasing hormone (LHRH) agonists 257

macrocephaly
mucopolysaccharidoses 56
Proteus syndrome 57
Sotos syndrome 56, 57
magical thinking 93
maintaining variables 223
major depressive disorder (MDD)
differential diagnosis 128–9
nonverbal behavior 103
prevalence and predisposing factors 127–8
traumatic brain injury (TBI) 81
treatment 129–33
mania 17
Marfan’s syndrome 61
matchbox sign 179
meclizine
traumatic brain injury (TBI) 87
medical assessment 26–7, 46–7
behavioral presentations 30–1
clinical pearls 47
interviewing techniques 116–17
laboratory testing 32–3
organ system review
cancer 44–5
diabetes mellitus 38
gastrointestinal system 39–41
menstrual-related issues 41–4

metabolic changes and cardiovascular system 33–7
osteoporosis 45
pulmonary system 38–9
sensory deficits 45–6
prevalence of ID conditions 33
primary care evaluation and preventive health planning 31–2
side effects of medication 33
syndrome-specific conditions
autism spectrum disorders (ASDs) 355–6
Down syndrome (DS) 27–8, 36, 339–40
Fragile X syndrome (FXS) 28, 34–5
Prader–Willi syndrome (PWS) 29, 36–7
Williams syndrome (WS) 29–31, 344
medication side effects 33
medroxyprogesterone 257
memory issues 286
evaluation 113–14
interactions during treatment 114–15
saliency 114
memory aids 286–7
menopause, early 27
menstruation 41–4
clinical vignette 43–4
mental defectives 1
mental examination 97
interpreting findings
mild ID 97–101
moderate ID 101
severe/profound ID 102–4
summary 98–9
mental health (MH) care delivery systems 11
mental illness
historical perspective
pre-Enlightenment ideas 1–3
reformers 3–4
interface with intellectual disability (ID) 11–12
mental retardation see intellectual disability (ID)
mental weakness 170
metabolic changes 33–7
metabolic syndrome 38
metachromatic leukodystrophy 58
microcephaly
fetal alcohol syndrome 57–8
Rett syndrome 57
mild ID (mental retardation) 5
clinical description 6
diagnostic criteria 5
diagnostic guidelines 6
mental status examination findings 97–101
mild mental subnormality 6
mindfulness 294
mirror (psychodrama technique) 299
mirtazapine 22
mitral valve prolapse 28
modeling 291
moderate ID (mental retardation) 5
clinical description 6–7
diagnostic criteria 5
diagnostic guidelines 7
mental status examination findings 101
moderate mental subnormality 7
moderate oligophrenia 7
mood disorders 125–6, 141
aggression 218
bipolar disorder (BD) and ID
prevalence and predisposing factors 133–5
treatments 138–41
MDD and ID
differential diagnosis 128–9
prevalence and predisposing factors 127–8
treatment 129–33
mood stabilizers
aggression 235–6
ID 264–5
Mood, Interest, and Pleasure Questionnaire (MIPQ) 18, 19
Motivation Analysis Rating Scale (MARS) 18
Motivational Assessment Scale (MAS) 18, 312
motivational interviewing (MI) 287–90
mucopolysaccharidoses 56
myoclonus 59
myosis 28

nadolol
aggression 238
naltrexone
aggression 237
narcissistic personality disorder 192
neurocutaneous depigmented macules 55
neurofibromatosis 54–5
neuroleptic-induced movement disorders
assessment and treatment 64–7
neuroleptic malignant syndrome 231
neurologic conditions 51, 68
abnormal head circumference
macrocephaly 56–7
microcephaly 57–8
dysmorphic features 51
Angelman syndrome 52–3
Cornelia de Lange syndrome (Bachman–de Lang syndrome) 52
DiGeorge syndrome 53–4
Fragile X syndrome (FXS) 52
Prader–Willi syndrome 52
velo-cardio-facial syndrome 53–4
Williams syndrome (WS) 53
examination of patients
cranial nerves 60–2
initial observation 60
motor disorders 62

motor syndromes 58
atonia/agenesis of corpus callosum 59
Huntington’s disease (HD) 58
myoclonus 59
Wilson’s disease 58
neurocutaneous stigmata
ataxia-telangiectasia 56
tuberous sclerosis 55
neuroleptic-induced movement disorders, assessment and treatment 64–7
seizure disorders 67–8
soft signs 59
autism 59
basal-ganglia-related disorders 59
cerebellar disorders 59
spasticity, management of 62–4
Nieman–Pick disease 61, 62
Nisonger Child Behavioral Rating Form (NCBRF) 18
nomenclature 8–10
non-steroidal anti-inflammatory drugs (NSAIDs)
menstrual problems 43
nonverbal communication 15, 103
Noonan’s syndrome 60
nortriptyline 130
nutrition and activity education (NAE) 36
nystagmus 61

obsessive compulsive disorder (OCD) 150–1
clinical vignette 152
research within ID population 151–2
oculogyric crisis 66
olanzapine 22–3, 34
aggression 233, 234
psychotic disorders 186
open-ended questions 115–16
opioid antagonists
aggression 237
oppositional defiant disorder (ODD) 234
osteoporosis 45
Othello Syndrome 179
ovarian failure, premature (POF) 28

panic disorder 149–50
Panicocolau tests 33
papilledema 61
paranoia 171
paranoid personality disorder 192
Parkinsonian syndrome 65
Parkinson’s disease 22–3
paroxetine 139
anxiety disorders 156
partial fetal alcohol syndrome (pFAS) 346
Index

passive personality disorder 192
Pelizaeus–Merzbacher disease 61
People First 4
People First language 10–11
peptic ulcers 40
perphenazine
agression 233
personality disorders 21, 191–2, 207
antisocial personality disorder (APD) 201–3
assessment 193–4
diagnostic criteria 194
structured assessment of personality
(SAP) 194
borderline personality disorder (BPD) 195–9
classification 192
diagnosis in persons with ID 194–5
DC-LD criteria 195
histrionic personality disorder (HPD) 200–1
prevalence 192–3
treatment 203–7
four-stage format 206
invalidating environment 204, 205
personality traits
influence on interview behavior 105
Pervasive Developmental Disorder Not Otherwise Specified
self-stimulation 169
phakomas 61
phenobarbital 139
pneumonia 38
port-wine hemangiomas 55
Positive and Negative Syndrome Scale (PANSS) 18
post-traumatic amnesia (PTA) 77
post-traumatic stress disorder (PTSD) 152–4, 303–4
clinical vignette 153–4
nonverbal behavior 103
traumatic brain injury (TBI) 81–2
Prader–Willi syndrome (PWS) 29, 36–7, 52
self-injurious behavior (SIB) 219
prazosin
traumatic brain injury (TBI) 87
pre-logical thinking 93
premature aging 27
premature ovarian failure (POF) 28
prevalence of ID 4–5
preventive health planning 31–2
primary care evaluation for ID 31–2
profound ID (mental retardation) 5
clinical description 7–8
diagnostic criteria 5
diagnostic guidelines 8
mental status examination findings 102–3
facial expressions 103–4
nonverbal communication 103
profound mental subnormality 8
profound oligophrenia 8
progestins 257
propranolol
agression 238
prostate cancer 44–5
Proteus syndrome 57
psychiatric assessment 14–15, 23
psychiatric assessment
see also diagnosis of ID (mental retardation);
medical assessment
challenges 15
differential diagnosis 21
history taking 16–18
interview 15–16
psychiatric assessment instruments,
standardised 18
mental status examination
cognition 20
diagnostic studies 20–1
insight and judgment 20
mood and affect 19
observation 19
orientation 19
risk of harm 20
thought disorder 19
personality factors and disorders 21
stressful life events 22–3
psychiatric assessment of Dual Diagnosis (ADD) 18
Psychiatric Assessment Schedule for Adults with Developmental Disabilities (PAS-ADD) 18
psychodrama techniques 299
psychological masking 95
Psychopathology Instrument for Mentally Retarded Adults (PIMRA) 18
Informant (PIMRA-I) 18
Self-report (PIMRA-SR) 18
psychosis
psychiatric assessment instruments 18
psychosocial masking 15, 17
psychostimulants
agression 238–9
psychotherapy 278–9, 304–5
barriers to treatment
confidentiality 283
lack of understanding of purpose 283
multiple care provider involvement 282–3
referral process 282
communication issues 283–5
feeling states 285–6
issues related to ID
impact on family 279–80
impact on individual 280–1
learning and memory issues 286
psychotherapy (Continued)
collaboration with caregivers 287
memory aids 286–7
psychotherapy topics and ID
grief and loss issues 298–302
trauma 302–4
treatment approaches 281–2
types 287
cognitive behavioral therapy (CBT) 290–3
dialectical behavior therapy (DBT) 293–5
group therapy 297–8
motivational interviewing (MI) 287–90
supportive psychotherapy (SP) 295–7
psychotic disorders 187
aggression 218
brief psychotic disorder 180
cultural issues 180–1
clinical pearls
differential diagnosis 167, 169
delusional disorder 179
diagnosis 162
caregiver interview 165–6
diagnostic overshadowing 163
patient interview 163–5
diagnostic manual–intellectual disability (DM-ID) 170
differential diagnosis
clinical pearls 167, 169
problem behaviors 167–9
self-stimulation 169
due to general medical condition (GMC) 183–4
exclusion from scientific literature 169–70
historical perspective 161–2
not otherwise specified (NOS) 185
prevalence 162
push for medication 166
schizoaffective disorder 178–9
schizophrenia
clinical pearls 172
current diagnosis 171
delusions 171–2
DSM-IV-TR and DM-ID diagnosis 173–6
hallucinations 171
historical perspective 170–1
subtypes 177
symptoms, disorganised 172
symptoms, negative 172
schizophreniform disorder 177–8
shared psychotic disorder (folie à deux) 181–3
substance-induced 184–5
treatments
medications 186
psychotherapy 186
safety 185
treatment team involvement 186–7
Psychotic Symptom Rating Scales (PSYRATS) 18
psychotropic medications in ID 250–1
anticonvulsants and mood stabilizers 264–5
clinical effects and complications 264
antidepressants and anxiolytics 266–9
clinical pearls 271–2
general principles 258–64
circumstances for medication use 264
relative receptor-binding affinities 262
guidelines 270–2
historical perspective 251
biopsychosocial model 252
pulmonary system 38–9
Questions About Behavior Functions (QABF) 312
questions, open-ended 115–16
quetiapine 34, 141
aggression 233, 234
Fragile X syndrome (FXS) 34
psychotic disorders 186
traumatic brain injury (TBI) 87
reflective listening 290
Reiss Screen for Maladaptive Behavior (RSMB) 18
relaxation for anxiety disorders 157
responsiveness 115
Rett syndrome 57
stereotypies 58
risk of harm 20
risperidone 22, 34, 139, 141
aggression 233, 234
role reversal (psychodrama technique) 299
rolling with resistance 289
Rubenstein–Taybe syndrome 61
sadness facial expression 104
Sapir–Whorf hypothesis of language 10
schemas 290
schizoaffective disorder 178–9
schizoid personality disorder 192
distribution 193
schizophrenia
clinical pearls 172
current diagnosis 171
delusions 171–2
DSM-IV-TR and DM-ID diagnosis 173–6
hallucinations 171
historical perspective 170–1
subtypes 177
symptoms, disorganised 172
symptoms, negative 172
schizophreniform disorder 177–8
shared psychotic disorder (folie à deux) 181–3
substance-induced 184–5
treatments
medications 186
psychotherapy 186
safety 185
treatment team involvement 186–7
Psychotic Symptom Rating Scales (PSYRATS) 18
psychotropic medications in ID 250–1
anticonvulsants and mood stabilizers 264–5
clinical effects and complications 264
antidepressants and anxiolytics 266–9
clinical pearls 271–2
general principles 258–64
circumstances for medication use 264
relative receptor-binding affinities 262
guidelines 270–2
historical perspective 251
biopsychosocial model 252
pulmonary system 38–9
Questions About Behavior Functions (QABF) 312
questions, open-ended 115–16
quetiapine 34, 141
aggression 233, 234
Fragile X syndrome (FXS) 34
psychotic disorders 186
traumatic brain injury (TBI) 87
reflective listening 290
Reiss Screen for Maladaptive Behavior (RSMB) 18
relaxation for anxiety disorders 157
responsiveness 115
Rett syndrome 57
stereotypies 58
risk of harm 20
risperidone 22, 34, 139, 141
aggression 233, 234
role reversal (psychodrama technique) 299
rolling with resistance 289
Rubenstein–Taybe syndrome 61
sadness facial expression 104
Sapir–Whorf hypothesis of language 10
schemas 290
schizoaffective disorder 178–9
schizoid personality disorder 192
distribution 193
schizophrenia
clinical pearls 172
current diagnosis 171
delusions 171–2
DSM-IV-TR and DM-ID diagnosis 173–6
hallucinations 171
historical perspective 170–1
subtypes 177
symptoms, disorganised 172
symptoms, negative 172
schizophreniform disorder 177–8
shared psychotic disorder (folie à deux) 181–3
substance-induced 184–5
treatments
medications 186
psychotherapy 186
safety 185
treatment team involvement 186–7
Index
Index

schizophreniform disorder 177–8
schizotypal personality disorder 192
scoliosis 29
selective serotonin reuptake inhibitors (SSRIs)
  aggression 232, 236
  ID 267
  premenstrual syndrome 43
  traumatic brain injury (TBI) 87
self-efficacy 289
self-injurious behavior (SIB) 212, 213
  associated syndromes 218–19
  persons with ID 214–16
  risk factors 219
Self-report Depression Questionnaire (SRDQ) 18
self-stimulation 169
sensory deficits 45–6, 117
sensory hypersensitivity 117
sertraline 130
  anxiety disorders 156
severe ID (mental retardation) 5
  clinical description 7
  diagnostic criteria 5
  diagnostic guidelines 7
  mental status examination findings 102–3
    facial expressions 103–4
    nonverbal communication 103
severe mental subnormality 7
severe oligophrenia 7
sexual aggression 256–8
shagreen patches 55
shared psychotic disorder (folie à deux) 181–3
short stature 60
sialorrhea 39
side effects of medication 33
silencing of genes 52–3
skin picking 29
sleep apnea 27, 38
Smith–Magenis syndrome 219
smoking 37
social skills 115
  training for aggression 230
societal reaction to mental illness and intellectual disability 1–3
Socratic questioning 291
soliloquizing (psychodrama technique) 299
somatic delusional disorder 179
Sotos syndrome 56, 60
  clinical vignette 57
spasticity
  management 62–4
spinocerebellar degeneration 61
static risk factors for aggression 219
stereotypies 58
stimulants
  traumatic brain injury (TBI) 87
strength of recommendation taxonomy (SORT) 32
Streptococcus pneumoniae 39
Struge–Weber syndrome 55–6
subacute sclerosing panencephalitis (SSPE) 59
substance-induced psychotic disorders 184–5
subvocalizations 110
summaries 290
supportive psychotherapy (SP) 295–7
surprise facial expression 104
sympathomimetic-induced psychosis 185
syndromes of ID 338, 359
  autism spectrum disorders (ASDs) 355
    behavioral phenotype 357–8
    cognitive functioning 357
    genetics 356–7
    medical issues 355–6
    psychopathology 358–9
Down syndrome (DS) 338–9
  behavioral phenotype 341
  cognitive functioning 340
  genetics 340
  medical issues 339–40
  psychopathology 341–3
fetal alcohol spectrum disorder (FASD) 345–6
  behavioral deficits 349–51
  cognitive deficits 348
  diagnosis 346–7
  medical conditions 347–8
Fragile X syndrome (FXS) 351
  behavioral phenotype 353
  cognitive functioning 352–3
  genetics 352
  medical issues 351–2
  psychopathology 353–5
Williams syndrome (WS) 343
  behavioral phenotype 344–5
  cognitive functioning 344
  medical issues 344
  psychopathology 345

tardive akathisia 65
tardive dyskinesia 64, 66
tardive dystonia 64
terminology 8–10
thorazine
  aggression 233
  tics 58
topiramate 139
  ID 264
town idiot 3
trauma 302–4
traumatic brain injury (TBI) 75, 88
  assessment and treatment 84–7
  causes 78
traumatic brain injury (Continued)
classification 78
clinical pearls
medications 86
questions 85
referrals 86
clinical presentation 79
compared with ID 76
co-occurring mental illness 82–3
definitions 76–7
mental health presentation 79–82
pharmacological management of symptoms 87
symptoms 81
treatments 4
aggression 240
electroconvulsive therapy (ECT) 239–40
aggression, hormonal 239
aggression, non-pharmacological 227–9
intervention levels 229
psychotherapy 229–31
aggression, pharmacologic
antidepressants 236–7
antipsychotic medications 232–4
benzodiazepines 237
beta blockers 238
mood stabilizers/anticonvulsants 235–6
opioid antagonists 237
overview 231–2
psychostimulants 238–9
anxiety disorders 155
pharmacologic interventions 155–7
psychotherapeutic interventions 157
bipolar disorder (BD) 138–41
pharmacotherapy 139–41
major depressive disorder (MDD) 129–33
cognitive behavioral therapy (CBT) 129–30
electroconvulsive therapy (ECT) 131
pharmacotherapy 130–1
memory 114–15
personality disorders 203–7
four-stage format 206
invalidating environment 204, 205

psychotherapy 281–2
psychotic disorders
medications 186
psychotherapy 186
safety 185
treatment team involvement 186–7
trepanation 2
tricyclic antidepressants 130
triptans
traumatic brain injury (TBI) 87
tuberous sclerosis 55
ulcers 40
Usher syndrome 61

valproate/valproic acid 139
aggression 235
ID 264
traumatic brain injury (TBI) 87
vanishing syndrome 223
velo-cardio-facial syndrome 53–4
venlafaxine 130, 141
Vineland Adaptive Behavior Scales 9
visual hallucinations 171
visual problems 45–6
vomiting blood 39

Williams syndrome (WS) 29–31, 53, 343
behavioral phenotype 344–5
clinical vignette 53
cognitive functioning 344
interviewing techniques 108
medical issues 344
psychopathology 345
Williams–Beuren syndrome 59
Wilson’s disease 58, 61
ziprasidone 34
aggression 233, 234
zolpidem
traumatic brain injury (TBI) 87